<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04382859</url>
  </required_header>
  <id_info>
    <org_study_id>WMed-2020-0601</org_study_id>
    <nct_id>NCT04382859</nct_id>
  </id_info>
  <brief_title>TOTEM: Trial of TAP Block Effective Medications</brief_title>
  <acronym>TOTEM</acronym>
  <official_title>TOTEM: Trial of TAP Block Effective Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Michigan University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western Michigan University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our goal is to determine if liposomal bupivacaine compared to standard bupivacaine results in
      increased pain control and decreased narcotic pain medication use when used in TAP blocks
      prior to laparoscopic hysterectomies for benign indications.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain rating 1 hour post operation</measure>
    <time_frame>1 hour post operation</time_frame>
    <description>Participant-reported pain rating on a numeric 0 - 10 scale, with rating of 0 representing no pain and rating 10 representing worst pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain rating 2 hours post operation</measure>
    <time_frame>2 hours post operation</time_frame>
    <description>Participant-reported pain rating on a numeric 0 - 10 scale, with rating of 0 representing no pain and rating 10 representing worst pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain rating 4 hours post operation</measure>
    <time_frame>4 hours post operation</time_frame>
    <description>Participant-reported pain rating on a numeric 0 - 10 scale, with rating of 0 representing no pain and rating 10 representing worst pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain rating 72 hours post operation</measure>
    <time_frame>72 hours post operation</time_frame>
    <description>Participant-reported pain rating on a numeric 0 - 10 scale, with rating of 0 representing no pain and rating 10 representing worst pain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>TAP block with liposomal bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAP block with 0.25% bupivacaine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transversus abdominis plane (TAP) block with liposomal bupivacaine</intervention_name>
    <description>Transversus abdominis plane (TAP) blocks are safe and effective procedures for the provision of postoperative pain management following abdominal procedures (3) and have been widely used across specialties with reduction in postoperative pain and narcotic use (4-7).</description>
    <arm_group_label>TAP block with 0.25% bupivacaine</arm_group_label>
    <arm_group_label>TAP block with liposomal bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women undergoing non robotic assisted laparoscopic surgery for benign gynecologic
             conditions

          -  English speaking

        Exclusion Criteria:

          -  Known current malignancy

          -  Contraindication to medications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melinda Abernethy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Michigan University Homer Stryker M.D. School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melinda Abernethy, MD</last_name>
    <phone>(919) 260-9328</phone>
    <email>melinda.abernethy@med.wmich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Melinda Abernethy, MD</last_name>
      <phone>919-260-9328</phone>
      <email>melnda.abernethy@med.wmich.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western Michigan University School of Medicine</investigator_affiliation>
    <investigator_full_name>Melinda Abernethy</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

